S1pr1 LoxP (S1pr1 tm2Rlp) Mouse
A conditional knockout mouse for S1pr1Sphingosine-1-phosphate (S1P) is a potent bioactive lipid that activates a family of G-protein coupled receptors, S1P1, S1P2, S1P3, S1P4 and S1P5. The S1P1 receptor is widely expressed and has critical functions in the immune, cardiovascular and nervous systems. It is a target for Fingolimod (brand name: Gilenya???), an immunomodulating drug, FDA approved for treating multiple sclerosis. The S1pr1 knockout mouse and the S1pr1 floxed mouse are useful for studying the function of the S1P1 receptor.Mice with a floxed S1P1 receptor gene were mated with mice expressing Cre-recombinase only ...
Source: NIDDK Research Resources - February 16, 2017 Category: Endocrinology Source Type: research
S1pr1 KO (S1pr1 tm1Rlp) Mouse
A Sphingosine-1-phosphate Receptor-1 (S1pr1) knockout mouseSphingosine-1-phosphate (S1P) is a potent bioactive lipid that activates a family of G-protein coupled receptors, S1P1, S1P2, S1P3, S1P4 and S1P5. The S1P1 receptor is widely expressed and has critical functions in the immune, cardiovascular and nervous systems. It is a target for Fingolimod (brand name: Gilenya???), an immunomodulating drug, FDA approved for treating multiple sclerosis. The S1pr1 knockout mouse and the S1pr1 floxed mouse are useful for studying the function of the S1P1 receptor. (Source: NIDDK Research Resources)
Source: NIDDK Research Resources - February 16, 2017 Category: Endocrinology Source Type: research
S1pr1 KO (S1pr1 tm1Rlp) Mouse
A Sphingosine-1-phosphate Receptor-1 (S1pr1) knockout mouseSphingosine-1-phosphate (S1P) is a potent bioactive lipid that activates a family of G-protein coupled receptors, S1P1, S1P2, S1P3, S1P4 and S1P5. The S1P1 receptor is widely expressed and has critical functions in the immune, cardiovascular and nervous systems. It is a target for Fingolimod (brand name: Gilenya???), an immunomodulating drug, FDA approved for treating multiple sclerosis. The S1pr1 knockout mouse and the S1pr1 floxed mouse are useful for studying the function of the S1P1 receptor. (Source: NIDDK Research Resources)
Source: NIDDK Research Resources - February 16, 2017 Category: Endocrinology Source Type: research
Receptors that regulate cell signaling relating to chemokines (U.S. Patent Number 6,365,356)
A method for discovering molecules that regulate cell signaling specific to the dual presence of Duffy antigen receptor for chemokines (DARC) and a chemokine receptor selected from the group consisting of a CXC receptor, a CC receptor and a CXXXC receptor, the method comprising providing a cell that co-expresses DARC and the chemokine receptor; incubating the molecules with the cell; measuring the cell signaling in the cell specific to the dual presence of DARC and the chemokine receptor; and determining whether the cell signaling specific to the dual presence of DARC and the chemokine receptor is regulated by the molecule...
Source: NIDDK Research Resources - February 16, 2017 Category: Endocrinology Source Type: research
Rapid method for diagnosing the various forms of alpha-thalassemia (U.S. Patent Number 6,322,981)
The present invention relates to the simultaneous and specific identification of the variant forms of α-thalassemia. This invention utilizes simple and readily available equipment to rapidly identify, diagnose and differentiate the different forms of α-thalassemia. Specifically, the present invention relates to a simple and rapid non-radioisotopic technique for the diagnosis and differentiation of the common forms of α-thalassemia has been developed. This approach works on any biological tissue including blood, wherein the assay works equally well with fresh blood and dried blood samples stored on filter paper. (Source:...
Source: NIDDK Research Resources - February 16, 2017 Category: Endocrinology Source Type: research
Purine Derivatives as A3 Receptor-selective Agonists (U.S. Patent Application Number 13/371,081)
Disclosed are (N)-methanocarba adenine nucleosides, e.g., of formula (I) as highly potent A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein R1-R6 are as defined in the specification. These nucleosides exhibit similar selectivities as agonists of the A3 versus the A1 receptor for both human and mouse adenosine receptors, and are contemplated for use in the treatment a number of diseases, for example, inflammation, cardiac ischemia, stroke, asthma, diabetes, and cardiac arrhythmias. (Source: NIDDK Research Resources)
Source: NIDDK Research Resources - February 16, 2017 Category: Endocrinology Source Type: research
Programmable self-assembled nanostructures based on sidechain-modified pna for the multivalent display of ligands (U.S. Patent Number EP 2569328 A2)
The invention concerns compositions comprising strands of polynucleotide and strands of PNA, each PNA strand comprising:(i) from 2 to 50 nucleobase subunits and(ii) one or more gamma substituents.The PNA strands are complementary to at least a portion of at least some of the polynucleotide strands, and the molar ratio of PNA strands to polynucleotide strands being at least 1:1. Certain gamma substituents are capable of effecting attachment of a PNA strand to a cell. The invention also concerns construction of nanostructure platforms and vaccines and use of the inventive compositions in inhibiting disease states in mammals....
Source: NIDDK Research Resources - February 16, 2017 Category: Endocrinology Source Type: research
Private Sector Collaboration with Eli Lily
Collaboration on the development of a transgenic model of tau pathology and tau-mediated neurodegeneration. Each party contributed a mouse model which were crossed. The resulting offspring underwent biochemical and immunohistochemical measurement of tau pathology and neurodegeneration, together with behavioural and/or locomotor testing of function. (Source: NIDDK Research Resources)
Source: NIDDK Research Resources - February 16, 2017 Category: Endocrinology Source Type: research
Polycystic kidney disease gene and protein (U.S. Patent Number 6,071,717)
The present invention involves isolated nucleic acid encoding human PKD1, and sequences derived therefrom. The invention also encompasses vectors comprising these nucleic acids, host cells transformed with the vectors, and methods for producing PKD1 protein or fragments thereof. In another aspect, the invention involves isolated oligonucleotides that hybridize only to the authentic expressed PKD1 gene, and not to PKD1 homologues. In yet another aspect, the invention involves isolated mutant PKD1 genes, and their cDNA cognates. Further provided are isolated oligonucleotides that discriminate between normal and mutant versio...
Source: NIDDK Research Resources - February 16, 2017 Category: Endocrinology Source Type: research
Polycystic kidney disease gene (U.S. Patent Number 5,654,170)
The present invention involves isolated nucleic acid encoding human PKD1, and sequences derived therefrom. The invention also encompasses vectors comprising these nucleic acids, host cells transformed with the vectors, and methods for producing PKD1 protein or fragments thereof. In another aspect, the invention involves isolated oligonucleotides that hybridize only to the authentic expressed PKD1 gene, and not to PKD1 homologues. In yet another aspect, the invention involves isolated mutant PKD1 genes, and their cDNA cognates. Further provided are isolated oligonucleotides that discriminate between normal and mutant versio...
Source: NIDDK Research Resources - February 16, 2017 Category: Endocrinology Source Type: research
Polycystic kidney disease gene (Patent Number 6,867,288)
The present invention provides methods and compositions for treating cyst formation in PKD1-associated epithelial cells. Such methods encompass administering an isolated human PKD1 gene, or fragments of the gene, under conditions that result in expression of therapeutically effective amounts of all, or part of, the PKD1 protein. The invention also encompasses compositions for treating cyst formation associated with APKD. For more information please contactJohns Hopkins University's Technology Ventures office. (Source: NIDDK Research Resources)
Source: NIDDK Research Resources - February 16, 2017 Category: Endocrinology Source Type: research
Podocin-rtTA (Tg(NPHS2-rtTA2*M2)1Jbk Mouse
Reverse tetracycline-controlled transgenic mouse model (Tet-On) under the control of the specific promoter for the glomerular podocyte protein (Podocin, NPHS2).Podocytes are post-mitotic epithelial cells that are positioned on the exterior aspect of the glomerular capillary wall and contribute to the selective molecular permeability of glomeruli. Podocyte damage or dysfunction results in loss of the characteristic foot processes that normally interdigitate and form the selective permeability barriers composed of filtration slits bridged by slit diaphragms. Minimal damage causes proteinuria that, in the case of minimal chan...
Source: NIDDK Research Resources - February 16, 2017 Category: Endocrinology Source Type: research
Podocin-rtTA (Tg(NPHS2-rtTA2*M2)1Jbk Mouse
Reverse tetracycline-controlled transgenic mouse model (Tet-On) under the control of the specific promoter for the glomerular podocyte protein (Podocin, NPHS2).Podocytes are post-mitotic epithelial cells that are positioned on the exterior aspect of the glomerular capillary wall and contribute to the selective molecular permeability of glomeruli. Podocyte damage or dysfunction results in loss of the characteristic foot processes that normally interdigitate and form the selective permeability barriers composed of filtration slits bridged by slit diaphragms. Minimal damage causes proteinuria that, in the case of minimal chan...
Source: NIDDK Research Resources - February 16, 2017 Category: Endocrinology Source Type: research
PNA-Detection of Pathogens (U.S. Patent Number 13/592,490)
The laboratory of Daniel Appella, PhD. has developed a prototype HIV testing kit that employs a peptide nucleic acid probe to capture HIV RNA recovered from patient blood. The probe targets a highly conserved segment of the Gag sequence. Initial data from tests run side by side with PCR show high sensitivity and specificity. The test, excluding the cost for an RNA extraction kit, has been calculated to be under $0.70 per sample based on retail price lists for reagents. This is within the cost target suggested by the World Health Organization. It is hoped that the test would be suitable for use in a developing country. Whil...
Source: NIDDK Research Resources - February 16, 2017 Category: Endocrinology Source Type: research
Pkd mutations and evaluation of same (U.S. Patent Number 20100047785 A1)
The present invention relates to methods of detecting novel mutations in a PKD1 and/or PKD2 gene that have been determined to be associated with autosomal dominant polycystic kidney disease (ADPKD) in order to detect or predict the occurrence of ADPKD in an individual. For more information please contactJohns Hopkins University's Technology Ventures office. (Source: NIDDK Research Resources)
Source: NIDDK Research Resources - February 16, 2017 Category: Endocrinology Source Type: research
